Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharma company making headlines in cardiometabolic and GI oncology. Today, the company reported financial results for the first quarter of 2025. In addition, it provided a strategic update on recent clinical and business developments.
Pipeline and Business Highlights
Galmed recently announced new preclinical data involving its lead candidate, Aramchol. Specifically, the data showed that Aramchol demonstrated synergistic anti-tumor effects when combined with regorafenib. Regorafenib, an FDA-approved oral cancer therapy, is used to treat gastrointestinal and liver tumors by blocking tumor growth and blood vessel formation.
As a result, Aramchol may have potential as part of a combination therapy approach in GI oncology.
Separately, Galmed also signed a term sheet to develop a novel sublingual formulation of semaglutide. This strategic move expands the company’s pipeline into the cardiometabolic disease space.
Continued Momentum in 2025
In addition to the Q1 updates, Galmed has reported several recent milestones:
- Positive Part 1 results from the AM-001 study of Aramchol Meglumine
- Galmed launched a collaboration with Virginia Commonwealth University (VCU) to study Aramchol’s potential to overcome drug resistance in GI cancers.
- Additionally, the company reported preclinical data showing anti-fibrotic effects of Aramchol in models of primary sclerosing cholangitis (PSC).
These updates highlight Aramchol’s potential across multiple therapeutic areas. They also reflect Galmed’s increasing focus on oncology and metabolic innovation.
First Quarter 2025 Financial Results
- Cash and equivalents were $15.9 million as of March 31, 2025. With an additional $5.0 million raised in May, the company’s current cash position totals approximately $20.1 million
- Net loss for the quarter was $1.1 million, or $0.62 per share, compared to $1.3 million, or $2.76 per share, in Q1 2024
- R&D expenses remained stable at $0.6 million
- G&A expenses decreased to $0.6 million from $0.8 million, primarily due to reduced professional services
- Net financial income increased to $0.2 million, up from $0.1 million in the prior year
Galmed is featured in the PRISM Pharmaceuticals Index.
The post Galmed Targets Oncology and Metabolic Disease with Semaglutide Agreement appeared first on PRISM MarketView.
